" class="no-js "lang="en-US"> Thomas Muster - Medtech Alert
Thursday, March 28, 2024
Thomas Muster

Thomas Muster

About Thomas Muster

PhD in Biotechnology and Associate Professor for Virology. Positions as Research Fellow at the Mount Sinai School of Medicine in New York, Staff Investigator of the Virology Group at the Institute of Applied Microbiology at the University of Applied Life Sciences and at the Department of Dermatology at the Medical University in Vienna. Founder and CEO of AVIR Green Hills Biotechnology and BlueSky Immunotherapies. Currently CEO of BlueSky Immunotherapies and CSO of Vivaldi Biosciences. More than 20 key inventions in vaccine development such as the discovery of a conserved antigen on HIV, a melanoma-associated retrovirus, and the interferon antagonist NS1 of influenza virus. Co-authored more than fifty publications in the fields of virology and oncology. Successfully steered the development of the live attenuated influenza vaccine deltaFLU and the cancer immunotherapy candidate delNS/E6E7 from discovery into clinical trials.

Related Story

Equine Sarcoids - Visible Success with DelNS-based Immunotherapy Leads the Way Towards Cancer Therapy in Humans

December 10 2021

Scientists from the Viennese biotech company BlueSky Immunotherapies GmbH (Ltd.) have used their viral vector platform delNS […]